HLB subsidiary Elevar Therapeutics has submitted a new drug application to the US Food and Drug Administration for its rivoceranib drug candidate plus camrelizumab as a first-line treatment for unresectable hepatocellular carcinoma (uHCC), which is the most common type of liver cancer.
Please refer to the following website for further details: Elevar submits new drug application for uHCC combo therapy (pharmaceutical-technology.com)